143 related articles for article (PubMed ID: 28790411)
1. Prognostic value of a 25-gene assay in patients with gastric cancer after curative resection.
Wang X; Liu Y; Niu Z; Fu R; Jia Y; Zhang L; Shao D; Du H; Hu Y; Xing X; Cheng X; Li L; Guo T; Li Z; Ji Q; Zhang L; Ji J
Sci Rep; 2017 Aug; 7(1):7515. PubMed ID: 28790411
[TBL] [Abstract][Full Text] [Related]
2. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
[TBL] [Abstract][Full Text] [Related]
3. Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study.
Zhu L; Wang H; Jiang C; Li W; Zhai S; Cai X; Wang X; Liao L; Tao F; Jin D; Chen G; Xia Y; Mao JH; Li B; Wang P; Hang B
EBioMedicine; 2020 Nov; 61():103023. PubMed ID: 33069062
[TBL] [Abstract][Full Text] [Related]
4. Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit.
Jiang Y; Xie J; Han Z; Liu W; Xi S; Huang L; Huang W; Lin T; Zhao L; Hu Y; Yu J; Zhang Q; Li T; Cai S; Li G
Clin Cancer Res; 2018 Nov; 24(22):5574-5584. PubMed ID: 30042208
[No Abstract] [Full Text] [Related]
5. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
6. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
[TBL] [Abstract][Full Text] [Related]
7. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
[TBL] [Abstract][Full Text] [Related]
8. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
[TBL] [Abstract][Full Text] [Related]
9. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.
Yan H; Chen Y; Yang Z; Li Z; Che X; Xiao J; Liu Y; Qu X
Front Immunol; 2020; 11():621623. PubMed ID: 33613554
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating Neutrophils is Prognostic and Predictive for Postoperative Adjuvant Chemotherapy Benefit in Patients With Gastric Cancer.
Zhang H; Liu H; Shen Z; Lin C; Wang X; Qin J; Qin X; Xu J; Sun Y
Ann Surg; 2018 Feb; 267(2):311-318. PubMed ID: 27763900
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of IGF1R gene expression in patients with Stage II/III gastric cancer who receive curative surgery and adjuvant chemotherapy with S-1.
Numata K; Oshima T; Sakamaki K; Yoshihara K; Aoyama T; Hayashi T; Yamada T; Sato T; Cho H; Shiozawa M; Yoshikawa T; Rino Y; Kunisaki C; Akaike M; Imada T; Masuda M
J Cancer Res Clin Oncol; 2016 Feb; 142(2):415-22. PubMed ID: 26337161
[TBL] [Abstract][Full Text] [Related]
12. Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer.
Xie Y; Lu W; Wang S; Tang X; Tang H; Zhou Y; Moran C; Behrens C; Roth JA; Zhou Q; Johnson DH; Swisher SG; Heymach JV; Papadimitrakopoulou VA; Xiao G; Minna JD; Wistuba II
Clin Cancer Res; 2019 Jan; 25(1):150-157. PubMed ID: 30287547
[TBL] [Abstract][Full Text] [Related]
13. ImmunoScore Signature: A Prognostic and Predictive Tool in Gastric Cancer.
Jiang Y; Zhang Q; Hu Y; Li T; Yu J; Zhao L; Ye G; Deng H; Mou T; Cai S; Zhou Z; Liu H; Chen G; Li G; Qi X
Ann Surg; 2018 Mar; 267(3):504-513. PubMed ID: 28002059
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of
Katayama Y; Oshima T; Sakamaki K; Aoyama T; Sato T; Masudo K; Shiozawa M; Yoshikawa T; Rino Y; Imada T; Masuda M
In Vivo; 2017; 31(4):565-571. PubMed ID: 28652421
[TBL] [Abstract][Full Text] [Related]
15. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of candidate microRNAs in gastric cancer: A validation study.
Zhang L; Huang Z; Zhang H; Zhu M; Zhu W; Zhou X; Liu P
Cancer Biomark; 2017; 18(3):221-230. PubMed ID: 27983528
[TBL] [Abstract][Full Text] [Related]
17. Identification of a molecular signature of prognostic subtypes in diffuse-type gastric cancer.
Kim SK; Kim HJ; Park JL; Heo H; Kim SY; Lee SI; Song KS; Kim WH; Kim YS
Gastric Cancer; 2020 May; 23(3):473-482. PubMed ID: 31773340
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of Tensin 4 Gene Expression in Patients with Gastric Cancer.
Sawazaki S; Oshima T; Sakamaki K; Aoyama T; Sato T; Shiozawa M; Yoshikawa T; Rino Y; Imada T; Masuda M
In Vivo; 2017; 31(6):1065-1071. PubMed ID: 29102927
[TBL] [Abstract][Full Text] [Related]
19. KRT17 as a prognostic biomarker for stage II colorectal cancer.
Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
Ohrling K; Edler D; Hallström M; Ragnhammar P
Acta Oncol; 2010 Aug; 49(6):797-804. PubMed ID: 20307245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
